Identifying Antibiotic Effects of Investigational Drugs on Commensal Bacteria with Machine Learning
- 24 June 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (7) , 1756-1766
Abstract
Many human-targeted medications have been found to impact patients’ gastrointestinal microbiomes, which has been proposed as an unrecognized source of drug side effects, comorbidities, and reduced treatment efficiencies. However, current methods for detecting such effects, such as patient sample analysis or in vitro high-throughput screening, are both labor- and resource-intensive. To accelerate the discovery of drug effects on the microbiome, we developed machine learning models that predict whether a small, drug-like molecule is likely to inhibit the growth of any of 40 representative human gut commensal microbes. We employed these models to virtually screen thousands of investigational drugs, revealing a strong propensity for human-targeted compounds to potentially modulate commensal microbes. Prospective in vitro validations uncovered two nonantibiotic drugs, the recently approved anti-cancer agent entrectinib and the clinical drug candidate PSI-697, to have previously unknown growth inhibition effects on multiple commensal gut microbes. Furthermore, we show that resistance to the effects of these drugs is mediated by known antibiotic resistance mechanisms BamB and TolC. Additionally, entrectinib significantly reduced microbial richness in a synthetic microbial model community. Taken together, our machine learning-assisted workflow and future extensions can triage microbiome-drug interactions to prioritize experimental testing and validation.Keywords
All Related Versions
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK136231)
- Duke Endowment
- Duke Department of Biomedical Engineering
This publication has 56 references indexed in Scilit:
- Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its ExtensionJournal of Bone and Mineral Research, 2020
- Machine Learning Uncovers Food- and Excipient-Drug InteractionsCell Reports, 2020
- A Deep Learning Approach to Antibiotic DiscoveryCell, 2020
- Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data SetsMolecular Pharmaceutics, 2017
- A Common Platform for Antibiotic Dereplication and Adjuvant DiscoveryCell Chemical Biology, 2017
- Shotgun Metagenomics of 250 Adult Twins Reveals Genetic and Environmental Impacts on the Gut MicrobiomeCell Systems, 2016
- The influence of non-steroidal anti-inflammatory drugs on the gut microbiomeClinical Microbiology and Infection, 2016
- Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditureEBioMedicine, 2015
- A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid ArthritisArthritis & Rheumatology, 2015
- The Bam machine: A molecular cooperBiochimica et Biophysica Acta (BBA) - Biomembranes, 2012